- Home
- CNTB vs SER Comparison
CNTB vs SER Comparison
Compare CNTB & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- SER
- Stock Information
- Founded
- CNTB 2012
- SER 2017
- Country
- CNTB United States
- SER United States
- Employees
- CNTB N/A
- SER N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- SER Health Care
- Exchange
- CNTB Nasdaq
- SER Nasdaq
- Market Cap
- CNTB 55.2M
- SER 47.5M
- IPO Year
- CNTB 2021
- SER 2018
- Fundamental
- Price
- CNTB $0.81
- SER $4.64
- Analyst Decision
- CNTB Strong Buy
- SER Strong Buy
- Analyst Count
- CNTB 1
- SER 1
- Target Price
- CNTB $8.00
- SER $11.00
- AVG Volume (30 Days)
- CNTB 18.3K
- SER 8.7K
- Earning Date
- CNTB 04-15-2025
- SER 11-12-2024
- Dividend Yield
- CNTB N/A
- SER N/A
- EPS Growth
- CNTB N/A
- SER N/A
- EPS
- CNTB N/A
- SER N/A
- Revenue
- CNTB $24,116,000.00
- SER $3,157,500.00
- Revenue This Year
- CNTB N/A
- SER N/A
- Revenue Next Year
- CNTB $62.09
- SER N/A
- P/E Ratio
- CNTB N/A
- SER N/A
- Revenue Growth
- CNTB N/A
- SER 2454.55
- 52 Week Low
- CNTB $0.77
- SER $3.81
- 52 Week High
- CNTB $2.66
- SER $23.18
- Technical
- Relative Strength Index (RSI)
- CNTB 39.94
- SER 45.48
- Support Level
- CNTB $0.79
- SER $4.66
- Resistance Level
- CNTB $0.91
- SER $4.95
- Average True Range (ATR)
- CNTB 0.08
- SER 0.15
- MACD
- CNTB -0.00
- SER -0.00
- Stochastic Oscillator
- CNTB 26.15
- SER 0.00
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.